3Mahalati K, Belitsky P, Sketris I et al.Neoral monitoring by simplified sparse sampling area under the concentration-time curve[J].Transplantation,1999,68(1):55-62.
4Kahan BD, Keown P, Levy GA et al.Therapeutic drug monitoring of immunosuppressant drugs in clinical practice[J].Clin Ther,2002,24(3):330-50,discussion 329.
5Keown PA. New concepts in cyclosporine monitoring[J].Curr Opin Nephrol Hypertens,2002,11(6):619-29.
6Evans WE, McLeod HL. Pharmacogenomics-Drug disposition, drug targets and side effect[J].N Engl J Med, 2003,348(6):538-49.
7Weinshilboum R. Inheritance and drug response[J].N Engl J Med, 2003,348(6):529-37.
8Zhu B, Liu ZQ, Chen GL et al.The distribution and gender difference of CYP3A activity in Chinese subjects[J].Br J Clin Pharmacol,2003,55(3):264-9.
9Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression[J].Nat Genet,2001,27(4):383-91.
10Lamba JK, Lin YS, Schuetz EG et al.Genetic contribution to variable human CYP3A-mediated metabolism[J].Adv Drug Deliv Rev,2002,54(10):1271-94.
1KARAZNIEWICZ-LADA M, LUCZAK M, GLOWKA F. Phar- macokinetic studies of enantiomers of ibuprofen and its chiral me- tabolites in humans with different variants of genes coding CYP2C8 and CYP2C9 isoenzymes [ J]. Xenobiotica, 2009, 39 (6) :476 -485.
2BRENNER SS, HERRLINGER C, D1LGER K, et al. Influence of age and cytochrome P450 2C9 genotype on the steady-state dis- position of diclofenac and celecoxib [ J]. Clin Pharmacokinet, 2003, 42(3) :283 -292.
3KALYONCU AF, KARAKAYA G, YILMAZ E, et al. Analgesic intolerance with or without bronchial asthma: is there a marker? [J]. J Investig Allergol Clin lmmunol, 2003, 13 ( 3 ) : 162 - 169.
4WU HC, CHANG CH, TSAI RY, et al. Significant association of methylenetetrahydrofolate reductase single nucleotide polymor- phisms with prostate cancer susceptibility in Taiwan[ J]. Antican- cer Res, 2010, 30(9) :3573 -3577.
5TUKOYA J, CHLADEK J, HROCH M, et al. 677TT genotype is associated with elevated risk of methotrexate (MTX) toxicity in juvenile idiopathic arthritis: treatment outcome, erythrocyte con- centrations of MTX and folates, and MTHFR polymorphisms[ J]. J Rheumatol, 2010, 37(10) :2180 -2186.
6GHODKE Y, CHOPRA A, JOSHI K, et al. Are Thymidylate synthase and Methylene tetrahydrofolate reductase genes linked with methotrexate response (efficacy, toxicity) in Indian (Asi- an) rheumatoid arthritis patients? [ J]. Clin Rheumatol, 2008, 27(6) :787 -789.
7KUHN UD, ANSCHUTZ M, SCHMUCKER K, et al. Phenoty- ping with sulfasalazine-time dependence and relation to NAT2 pharmacogenetics[ J ]. lnt J Clin Pharmacol Ther, 2010, 48 (1) :1 -10.
8COWEN D, BEDINGFIELD P, MCCONKEY GA, et al. A study of the effects of substituents on the selectivity of the binding of N- arylaminomethylene malonate inhibitors to DHODH [ J ]. Bioorg Med Chem Lett, 2010, 20( 3 ) : 1284 - 1287.
9FAN HM, WANG Z, FENG FM, et al. Genetic evaluation of the TNF-α -238G > A and -308G > A promoter polymorphisms in Croatian patients with type I diabetes. Association of TNF-alpha- 238G/A and 308 G/A gene polymorphisms with pulmonary tuber- culosis among patients with coal worker's pneumoconiosis [ J ]. Biomed Environ Sci, 2010, 23(2) :137 -145.
10LEE YH, JI JD, BAE SC, et al. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and-238 G/A polymor- phisms and shared epitope status and responsiveness to TNF-al- pha blockers in rheumatoid arthritis: a metaanalysis update[ J]. J Rheumato1,2010, 37 (4) :740 - 746.
